Search hospitals > California > Santa Monica
UCLA
Claim this profileSanta Monica, California 90404
Global Leader in Non-Small Cell Lung Cancer
Global Leader in Cancer
Conducts research for Solid Tumors
Conducts research for Breast Cancer
Conducts research for Tumors
83 reported clinical trials
23 medical researchers
Summary
UCLA is a medical facility located in Santa Monica, California. This center is recognized for care of Non-Small Cell Lung Cancer, Cancer, Solid Tumors, Breast Cancer, Tumors and other specialties. UCLA is involved with conducting 83 clinical trials across 122 conditions. There are 23 research doctors associated with this hospital, such as Zev A. Wainberg, Lee Rosen, MD, J. Randolph Hecht, MD, and John Shen, M.D..Area of expertise
1Non-Small Cell Lung Cancer
Global LeaderStage IV
Stage III
EGFR positive
2Cancer
Global LeaderStage IV
Stage III
PD-L1
Top PIs
Zev A. WainbergUCLA2 years of reported clinical research
Expert in Solid Tumors
Studies Pancreatic Cancer
32 reported clinical trials
64 drugs studied
Lee Rosen, MDUCLA Department of Medicine2 years of reported clinical research
Studies Tumors
Studies Solid Tumors
9 reported clinical trials
21 drugs studied
J. Randolph Hecht, MDUCLA Medical Center2 years of reported clinical research
Studies Colorectal Cancer
Studies Non-Small Cell Lung Cancer
5 reported clinical trials
7 drugs studied
John Shen, M.D.UCLA Medical Center3 years of reported clinical research
Studies Prostate Cancer
Studies Squamous Cell Carcinoma
4 reported clinical trials
6 drugs studied
Clinical Trials running at UCLA
Breast Cancer
Colorectal Cancer
Non-Small Cell Lung Cancer
Solid Tumors
Sleep Apnea
Tumors
Obstructive Sleep Apnea
Cancer
Ovarian Cancer
Postoperative Pain
NGM707 + Pembrolizumab
for Cancer
This trial is testing a new drug called NGM707, both by itself and with another drug, Pembrolizumab. It targets patients with very advanced or spreading solid tumors. The treatment aims to boost the immune system to better fight cancer.
Recruiting1 award Phase 1 & 25 criteria
Atezolizumab + Trastuzumab Emtansine
for Breast Cancer
This is a Phase III, two-arm, randomized, double-blind placebo-controlled study in participants with HER2-positive primary breast cancer who have received preoperative chemotherapy and HER2-directed therapy, including trastuzumab followed by surgery, with a finding of residual invasive disease in the breast and/or axillary lymph nodes. As of June 4, 2024, this study is no longer accepting any newly screened participants.
Recruiting1 award Phase 35 criteria
Opt-In Narcotics Protocol
for Breast Surgery
In a recent study, researchers let patients choose what medications to go home with after endocrine surgery. This has not been done in outpatient breast surgery, though several institutions have moved towards avoiding opioids altogether after breast surgery. These institutions only prescribed rescue opioids upon request. The aim of this study is to compare a similar "opt-in" protocol for narcotics to usual care (where patients are routinely discharged with opioids) for outpatient breast surgery. This study will be designed as a randomized, controlled trial. When adult patients consent for outpatient breast surgery, the patients will be asked to participate in the study. Patients who are currently using narcotics would be excluded. The investigators would then randomize participants to the "opt-in" protocol versus being provided with a standard opioid prescription after surgery. Patients in the opt-in protocol will be recommended a pain treatment regimen with over-the-counter medications, acetaminophen or ibuprofen. These patients will be reassured that if their pain is uncontrolled after discharge, a narcotic prescription will be called in to their pharmacy if requested. The investigators will assess patient pain scores and medication use in the recovery area using the electronic medical record. The investigators will collect data on patient pain scores and medication use after discharge on a daily basis via phone call or electronically transmitted survey. The investigators will also evaluate patients at the time of their follow-up visits. Any patient phone calls will be routed to study personnel who will fill narcotic prescription requests if requested. Finally, among patients who do receive an opioid prescription, the investigators will track their opioid consumption.
Recruiting1 award N/A2 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at UCLA?
UCLA is a medical facility located in Santa Monica, California. This center is recognized for care of Non-Small Cell Lung Cancer, Cancer, Solid Tumors, Breast Cancer, Tumors and other specialties. UCLA is involved with conducting 83 clinical trials across 122 conditions. There are 23 research doctors associated with this hospital, such as Zev A. Wainberg, Lee Rosen, MD, J. Randolph Hecht, MD, and John Shen, M.D..